港股異動 | 中國先鋒醫藥(1345.HK)漲逾4% 簽訂防護口罩銷售合約
格隆匯5月5日丨中國先鋒醫藥(1345.HK)現報1.23港元,漲4.24%,暫成交250萬港元,最新總市值15.5億港元。公司5月3日晚間發公告稱,集團已與Angelina Environmental(以下簡稱“AE”)簽訂銷售合約,以向AE出售防護口罩,總金額約為259.6萬歐元。根據披露,AE為一間於西班牙註冊成立的公司,為COVEX的全資附屬公司。COVEX為一間西班牙化學制藥公司,主要從事生產及商業化經營API(原料藥)原材料、醫藥產品及營養補充品業務。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.